PharmTeam

Seth Robey

Seth has always had a passion for scientific discovery, particularly biology and medicine. Seth studied biochemistry at Brandeis University. Now, as a PhD student of Molecular Pharmacology at Columbia University, Seth studies the drugs that help treat cardiac arrhythmias. He's thrilled to be a Motley Fool Contributor, and uncover new and exciting scientific discoveries that could improve our approach to medicine, and provide strong long term investments. Follow @SethRobey on twitter.

PharmTeam’s Activity

Fri Oct 24

NL

Article

PharmTeam published an article 12:40 PM

3 Reasons Thermo Fisher Scientific Inc.'s Stock Could Tumble

Can Thermo Fisher Scientific execute on its massive growth opportunity, or will the doldrums of slow organic growth hold back its stock?

Thu Oct 23

NL

Article

PharmTeam published an article 11:59 AM

Eli Lilly & Co. Earnings: Patent Pains Continue

Eli Lilly has experienced one of the toughest patent loss challenges in the industry. Did they finally reach the bottom this quarter?

Wed Oct 22

NL

Article

PharmTeam published an article 6:15 PM

Thermo Fisher Scientific Inc.'s Earnings: Buying Its Way to the Top

The laboratory equipment juggernaut showed explosive growth, but the market wasn't so impressed. Does Wall Street have this one backwards?

NL

Article

PharmTeam published an article 12:49 PM

3 Reasons Thermo Fisher Scientific Inc.'s Stock Could Rise

Thermo Fisher Scientific's future rests on three pillars of growth, and a big-name acquisition may tip the scales in their favor.

Tue Oct 21

NL

Article

PharmTeam published an article 9:40 AM

Is It Time to Buy Eli Lilly & Co.'s Stock?

Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.

Mon Oct 20

NL

Article

PharmTeam published an article 3:00 PM

5 Things Thermo Fisher Scientific Inc.'s Management Wants You to Know

Thermo Fisher Scientific is in a strong position to exploit a growing genomics market. Management knows it -- and they really want you to know it, too.

Mon Sep 22

NL

Article

PharmTeam published an article 11:54 PM

3 Reasons Eli Lilly & Co.'s Stock Could Fall

Management at Eli Lilly & Co. has faced a mountain of challenges in the wake of debilitating patent losses, but the stock has held strong regardless. Here are three reasons that rally may not continue into the future.

Fri Aug 29

NL

Article

PharmTeam published an article 11:36 AM

3 Reasons Eli Lilly & Co.'s Stock Could Rise

With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?

Wed Aug 20

NL

Article

PharmTeam published an article 5:59 PM

5 Things Eli Lilly and Co's Management Wants You to Know

At a critical time for the company, Eli Lilly's management has laid out its plans to return to growth and gave us a good look at what the future holds.

Thu Aug 14

NL

Article

PharmTeam published an article 11:31 AM

3 Building Blocks of a Wearable Technology Revolution

The sky is the limit for wearable medical technology, but it won't be as simple as slapping a smart watch on your wrist.

Sat Jul 19

NL

Article

PharmTeam published an article 2:05 PM

10 Problems Electronic Health Records Can Help Solve

Electronic health records will be a central player in the future of health care and health care reform, and they may be even more useful than you might think.

Thu Jul 10

NL

Article

PharmTeam published an article 9:30 AM

Are Cancer Vaccines Worth an Investment?

Immuno-oncology has been the darling of biotech investors, but growth in one segment of the industry might not look as strong as you think.

Mon Jun 30

NL

Article

PharmTeam published an article 1:00 PM

Why Are Companion Diagnostics So Important?

Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?

Sun Jun 15

NL

Article

PharmTeam published an article 2:00 PM

Is Apple Disrupting Health Care's Disruptors?

With its new operating system and health app interface, Apple will enable doctors to play more of a role in patient-focused care. How will that change the landscape of health care IT providers?

Mon Jun 2

NL

Article

PharmTeam published an article 2:30 PM

ASCO 2014: Doubling Down on Next-Gen Cancer Drugs

What's better than a cancer treatment that binds specifically to its target? A therapy that specifically binds to two targets, of course.

NL

Article

PharmTeam published an article 9:35 AM

ASCO Showdown: AstraZeneca vs. Clovis Oncology

The annual meeting brings together some of the world's most exciting emerging cancer treatments, and after only a day AztraZenica and Clovis are making waves as the compete in the lung cancer market.

Wed May 28

NL

Article

PharmTeam published an article 4:35 PM

3 Biotechs Worthy of a Stanley Cup

If these three drug makers were hockey teams, you can bet they'd have what it takes to compete at hockey's highest level.

Fri Apr 25

NL

Article

PharmTeam published an article 2:30 PM

3 Questions About a Big Pharma Megamerger

From pipelines to competitive landscapes, here are three questions that could shape a huge acquisition and the markets they operate in.

Thu Mar 20

NL

Article

PharmTeam published an article 6:30 PM

A Major Confidence Boost for this Health Care IT Provider

Veeva Systems overcame two major hurdles in the most recent quarter. Is it time for smooth sailing?

Fri Mar 14

NL

Article

PharmTeam published an article 2:00 PM

The NIH is Investing in an Alzheimer's Cure; Should You?

Can any of the number of companies struggling to cure Alzheimer's disease provide reliable investments?

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 94.27
Player Rank 4312 out of 75185
Score 1181.49
Score Change Today -13.42
Accuracy 63.16%
Active Picks 54
Total Picks 76
Best Pick ILMN (+157.99)
Worst Pick SZYM (-95.24)
Average Score per Pick 15.55
Charms Earned 6
Highest Rated Favorite No Favorites Selected
Go to PharmTeam’s CAPS page

Boards Stats & Trivia

CAPS All Star
Board Posts 40
Recs Received 51
People who have rec'd these posts 30
Recs to Posts Ratio (last 30 days) N/A
Threads Started 14
Threads Started Percentage 35.00 %
Most Frequent Board Motley Fool Rule Breakers
Very First Post A SAS: Amazon.com post. (12/1/2013)
Percentage of Posts Rec'd 57.50 %
Show PharmTeam’s 10 Latest Posts